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Abstract A large two-stage GWAS by Antilla et al.
reported the minor allele of rs1835740 on 8q22.1 to be
associated with common types of migraine. The objective
of the present study was to determine the clinical correlate
of the variant in migraine without aura (MO). Clinical data
on 339 successfully genotyped MO patients (patients with
attacks of migraine without aura and no attacks of migraine
with aura) were obtained by an extensive validated semi-
structured telephone interview performed by a physician
or a trained senior medical student. Reliable, systematic
and extensive data on symptoms, age of onset, attack
frequencies and duration, relevant comorbidity, speciﬁc
provoking factors including different hormonal factors in
females, and effect and use of medication, both abortive
and prophylactic, were thereby obtained. A comparison of
carriers and non-carriers were performed. Comparison of
homozygotes with heterozygotes was not performed as the
number of homozygotes was too small for statistical pur-
poses. Data from other MO populations in the GWAS by
Antilla et al. were not included as phenotype and clinical
data were obtained differently. While thousands of patients
are needed to detect a genetic variant like rs1835740, 339
are sufﬁcient to detect meaningful clinical differences. 136
of 339 patients were carriers of the variant, 15 were homo-
zygous.Comparisonofcarriers with non-carriersshowedno
signiﬁcant difference in any of the parameters studied. In
conclusion, the rs1835740 variant has no signiﬁcant inﬂu-
ence on the clinical expression of MO.
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Introduction
Genetic factors have been demonstrated to play an
important role in the pathogenesis of migraine. The rare
familial hemiplegic migraine (FHM), deﬁned by the pres-
ence of a transient hemiplegia during the aura phase, is
dominantly inherited with at least four different genetic
subtypes [1]. In contrast, migraine without aura (MO) and
migraine with typical aura (MA) have multifactorial
inheritance [2–7]. The co-occurrence of MO and MA in
monozygotic and dizygotic twin pairs is not higher than
expected by chance, which together with the different
epidemiology and clinical features of the two indicates that
MO and MA are distinct disorders with some clinical and
etiological overlap [5, 8]. This study will concentrate on
MO. The inﬂuence of a genetic factor in MO is supported
by a twofold increased risk of MO in ﬁrst degree relatives
of probands with MO compared to the general population
[3]. Furthermore, the concordance rate of MO in mono-
zygotic twin pairs is signiﬁcantly higher than in dizygotic
twin pairs (28 vs. 18%) [9], and the heritability has been
estimated to 50% [2].
Until recently, no reproducible genetic association or
linkage has been reported in MO. However, a large two
stage genome-wide association study (GWAS) by Antilla
et al. reported the minor allele of rs1835740 on chromo-
some 8q22.1 to be associated with migraine with an overall
meta-analysis p value of 1.69 9 10
-11 [10]. The study
comprised case materials from ﬁve European countries,
2,731 migraine cases were included in the discovery stage
and 3,202 in the replication stage. The allele was found to
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migraine patients, MA patients without attacks of MO (MA
only), patients with attacks of both MA and MO, and MO
patients without attacks of MA (MO only).
The clinical correlate of this variant, if any, remains to
be determined. In our genetic studies, we have system-
atically collected extensive clinical data using a semi-
structured telephone interview by a physician. We are
thus able to report on the phenotype–genotype correlation
based on detailed clinical information in 339 patients with
MO and no attacks of MA from the Danish subsample.
The aim of the present study was thus to compare clinical
data in MO patients with and without the rs1835740
variant.
We have not attempted to include the other groups from
the two-stage GWAS in this analysis in that the pheno-
typing has been done differently and with different elabo-
ration on clinical features from group to group. Thus, it was
not possible to pool clinical data. If the difference in
clinical features between patients with and without the
variant is of any clinical importance, 339 patients should be
enough for this purpose.
Methods
Ascertainment of MO patients without attacks
of MA (MO only)
Patients having a MO diagnosis living in the eastern part of
Denmark were extracted from case ﬁles at the Danish
Headache Center. The recruited patients, all ethnical
Caucasians, received a posted letter stating that the
objective of the survey was to study the inheritance of
migraine and would involve a telephone interview and a
blood sample. They were asked to return a slip in a prepaid
envelope conﬁrming whether they agreed to participate.
606 patients were recruited and 407 agreed to participate,
corresponding to a response rate of 67.4%. These patients
were then contacted for an extensive semi-structured tele-
phone interview by a physician or a trained senior medical
student. The validated semi-structured telephone interview
was based on the diagnostic criteria of The International
Headache Society (IHS), and the diagnosis was given
according to the IHS 2004 criteria [11, 12]. A total of 360
patients were given the diagnosis MO. Of these, 56 were
excluded because of co-occurrence of MA. Thus, 304 were
given the diagnosis ‘MO only’ and included. In addition,
81 MO-only patients were diagnosed and included from
another study recruiting MA families using the same semi-
structured telephone interview [13]. The total number of
MO-only patients was thus 385. A blood sample was col-
lected from each of the 385 MO-only patients, and 340
were successfully genotyped. One was hereafter excluded
due to missing data; hence, the analysis in this study was
based on data in 339 MO-only patients. All subjects pro-
vided written informed consent. The project was approved
by the Danish Ethics Committees (application no. KA
94076m).
The two-stage GWAS
The method is fully published by Antilla et al. A short
description is given here to facilitate the understanding of
our work.
In the discovery stage, a clinic-based sample of 3,279
migraineurs from Finland, Germany and The Netherlands
was studied and genotyped at the Wellcome Trust Sanger
Institute using Illumina (610K and 550K) SNP microarrays
against 10,747 population-matched controls [10]. In the
replication stage, a further 3,202 migraineurs from Iceland
(using Illumina Human Hap 317K, 370K, 610K or 1M
bead arrays at deCODE genetics), Denmark (using Cen-
taurus platform [Nanogen inc.] at deCODE genetics), The
Netherlands (TaqMan technology [Applied Biosystems,
Life] at Leiden University Medical Center) and Germany
(Illumina HumanHap 610K array at the Institute of Human
Genetics at the Helmholtz Zentrum, Munich) were studied
against 40,062 population-matched controls.
The diagnoses were given by headache experts using a
combination of questionnaires and individual interviews
based on the IHS 2004 criteria [11]. The following diag-
nostic subgroups were analyzed: (1) all migraine patients
(‘all migraine’), (2) MA patients without attacks of MO
(‘MA only’), (3) patients with attacks of both MA and MO
(‘both MA and MO’), and (4) MO patients without attacks
of MA (‘MO only’).
For the meta-analysis of discovery and replication
samples the Cochran–Mantel–Haenszel (CMH) association
analysis with a signiﬁcance threshold of p B 5 9 10
-8 was
used. In the discovery sample, 2,731 cases and 10,747
controls passed quality control steps, and 429,912 markers
were successfully genotyped. Only one marker, rs1835740
on chromosome 8q22.1, showed signiﬁcant association
with migraine in the multi-population CMH analysis. The
minor allele (A) of marker rs1835740 was associated
with ‘all migraine’ with p = 5.38 9 10
-9 and odds ratios
ranging between 1.21 and 1.33. The result was conﬁrmed
in the replication study with a ﬁnal p = 1.69 9 10
-11 in
the CMH meta-analysis for all migraine sample together.
In the HapMap Phase II data [14], marker rs1835740 is
located between the two potentially interesting genes,
MTDH and PCGP, which are both involved in glutamate
homeostasis. The effect of the marker on gene expression
was analyzed in human ﬁbroblasts, primary T cells and
lymphoblastoid cell lines obtained from umbilical cords.
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cant correlation to higher MTDH expression in lympho-
blastoid cell lines.
Statistical methods
All data were processed and analyzed using Statistical
Package for the Social Sciences (SPSS) version 18.0 in
Windows 7.0. Two-tailed Student’s t test and one-way
ANOVA was used to compare means for numerical data.
v
2 test was used to compare categorical data.
A comparison of carriers of the rs1835740 variant with
non-carriers was performed. Thereafter carriers were sub-
divided into homo- and heterozygotes. No statistical tests
were performed on homozygotes versus heterozygotes as
the sample of homozygotes was too small. Finally, a sub-
analysis in females was done. Sub-analysis in males was
not performed as this sub-group was too small for a
meaningful analysis.
Results
136 out of 339 (40%) apparently non-related MO probands
were carriers of the rs1835740 variant, hereof 20 out of 47
males and 116 out of 292 females. Of the carriers, 15 were
homozygous (1 male and 14 females) and 121 were het-
erozygous (19 males and 102 females). In carriers, the
average age was 43.8 ± 12.8, and in non-carriers 43.6 ±
11.5, p = 0.880. The average age of onset in carriers was
20.9 ± 12.0, and in non-carriers 20.9 ± 10.6, p = 0.995.
The average duration of migraine was in the interval
4–23 h in 37.5% of carriers and in 36.9% of non-carriers,
and 1–3 days in 54.4% of carriers and in 56.7% in non-
carriers. Thus, carriers and non-carriers were comparable
in average age, age of onset and average duration of
migraine. Attack frequencies through life and during the
past year were also evenly distributed for carriers and non-
carriers (data not shown).
Table 1 summarizes the migraine-speciﬁc symptoms of
carriers versus non-carriers with corresponding p values,
and of homo- and heterozygotes, respectively. Table 2
describes the comorbidity. Provoking factors are described
in Table 3, hormonal factors in females in Table 4. The
effect and use of medicine is presented in Table 5.
No statistically signiﬁcant association with the A-allele
of rs1835740 was found in the comparison of carriers with
non-carriers for any of the parameters studied. However,
when carriers were divided in homo- and heterozygotes
and compared to non-carriers, a tendency that heterozy-
gotes were comparable to non-carriers, and that homozy-
gotes tended to differ in a non-signiﬁcant manner from
these two other groups, could be observed.
A sub-analysis in females (not shown) gave the same
results as in the whole material. No statistical calculations
were done in males because of their small number.
Numerically, males seemed to follow the general picture.
Discussion
No statistically signiﬁcant association with the A-allele
rs1835740 was found for any of the parameters that were
studied: symptoms, comorbidity, provoking factors or the
effect and use of different medical treatment. However,
while heterozygotes were comparable to non-carriers,
homozygotes tended to differ in a non-signiﬁcant manner
in some parameters. Homozygosity for the A-allele of
rs1835740 might thus have a small inﬂuence on the phe-
notype of MO, but it could easily be a false trend because
of the small number of homozygotes. The sub-analysis in
females did not show any difference from the overall
analysis, and the male sample was too small for statistical
calculation. Thus, the present study suggests that the
rs1835740 variant has no inﬂuence on the clinical expres-
sion of MO.
Why study MO as a separate entity?
It has been questioned whether MO and MA are two dis-
tinct disorders or a single entity [15, 16], but considerable
evidence supports the former. All together, the different
epidemiology, the different clinical features, difference in
comorbidity, the presence or absence of measurable corti-
cal spreading depression, different provoking factors, dif-
ferent effect of different preventive medicine and twin
studies showing lower concordance-rate in MO than in
MA, indicate that MO and MA are distinct disorders with
someclinicalandetiologicaloverlap[5,8,17–20].Therefore,
the present study concentrated on MO only.
The original large study by Antilla et al. showed consis-
tently stronger association with the presence of the
rs1835740 A-allele for MA-only groups [10]. The present
study indicates that the A-allele of rs1835740 probably has
no crucial inﬂuenceon the phenotype ofMO.Maybe studies
ofclinicalfeaturesinMAwillrevealamoreclear difference
according to the presence or absence of rs1835740 A-allele
in MA patients. This would further support the assumption
that MO and MA are distinct disorders.
Methodological considerations
In the absence of a biochemical marker or paraclinical test,
the diagnosis of migraine is purely clinical. The differential
diagnosis between tension-type headache (TTH) and
migraine is often difﬁcult, and also the differentiation
J Headache Pain (2012) 13:21–27 23
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extensive, validated, semi-structured telephone interview
performed by a physician or a trained senior medical stu-
dent [12]. Thus, our clinical data are reliable as well as
systematic and extensive.
The sample of MO patients in this study was recruited
from a specialized clinical sample and thus represents a
fairly severely affected group. We cannot exclude pheno-
typic differences between those with and without the var-
iant in a population of less affected individuals.
Table 1 Symptoms associated with attacks of migraine in ‘migraine without aura’ patients divided in subgroups: carriers and non-carriers of the
rs1835740 variant, and homo- and heterozygotes of the rs1835740 variant
Symptoms Carriers Non-carriers p* Homo Hetero Total number
of answers %( n)% ( n)% ( n)% ( n)
Unilateral location 83.9 (104) 87.7 (164) 0.338 80.0 (12) 84.4 (92) 311
Pulsating quality 81.0 (102) 82.6 (152) 0.710 71.4 (10) 82.1 (92) 310
Moderate or severe pain intensity 100.0 (136) 100.0 (203) _ 100.0 (15) 100.0 (121) 339
Aggravation by physical activity 91.0 (121) 93.0 (186) 0.500 80.0 (12) 92.4 (109) 333
Nausea 93.2 (124) 94.5 (188) 0.642 93.3 (14) 93.2 (110) 332
Vomiting 67.7 (86) 69.4 (127) 0.753 76.9 (10) 66.7 (76) 310
Photophobia 92.3 (120) 90.2 (175) 0.516 100.0 (14) 91.4 (106) 324
Phonophobia 88.4 (114) 82.7 (158) 0.165 100.0 (14) 87.0 (100) 320
Osmophobia 52.2 (59) 57.2 (97) 0.422 53.8 (7) 52.0 (52) 283
* p values for comparison of carriers and non-carriers
Table 2 Comorbidity in ‘migraine without aura’ patients divided in subgroups: carriers and non-carriers of the rs1835740 variant, and homo-
and heterozygotes of the rs1835740 variant
Comorbidity Carriers Non-carriers p* Homo Hetero Total number
of answers %( n)% ( n)% ( n)% ( n)
Comotio 44.9 (61) 41.0 (82) 0.483 33.3 (5) 46.3 (56) 336
Cranial fracture 1.5 (2) 1.0 (2) 0.696 0.0 (0) 1.7 (2) 336
Encephalitis 0.0 (0) 0.5 (1) 0.409 0.0 (0) 0.0 (0) 336
Meningitis 1.5 (2) 2.0 (4) 0.719 6.7 (1) 0.8 (1) 336
Cerebral thrombosis 0.7 (1) 0.0 (0) 0.225 0.0 (0) 0.8 (1) 336
Cerebral hemorrhage 0.0 (0) 0.0 (0) _ 0.0 (0) 0.0 (0) 336
Transient cerebral ischemia (TCI) 0.0 (0) 0.0 (0) _ 0.0 (0) 0.0 (0) 336
Arterial hypertension 10.3 (14) 16.5 (33) 0.107 0.0 (0) 11.6 (14) 336
Tension type headache (TTH) 65.4 (89) 73.6 (147) 0.106 86.7 (13) 62.8 (76) 337
* p values for comparison of carriers and non-carriers
Table 3 Migraine provoking factors in ‘migraine without aura’ patients divided in subgroups: carriers and non-carriers of the rs1835740 variant,
and homo- and heterozygotes of the rs1835740 variant
Provoking factors Carriers Non-carriers p* Homo Hetero Total number
of answers %( n)% ( n)% ( n)% ( n)
Attacks provokable 26.6 (29) 21.7 (26) 0.348 9.1 (1) 28.6 (28) 275
Physical activity 32.7 (37) 30.2 (51) 0.649 8.3 (1) 35.6 (36) 282
Stress 69.3 (79) 69.8 (120) 0.933 61.5 (8) 70.3 (71) 286
Weekend/holiday 49.6 (56) 51.5 (88) 0.753 53.8 (7) 49.0 (49) 284
Food 50.4 (57) 41.2 (70) 0.125 61.5 (8) 49.0 (49) 283
Alcohol 26.4 (29) 19.2 (32) 0.157 7.7 (1) 28.9 (28) 277
Hormonal factors, females only: menstrual migraine
a 51.5 (50) 56.7 (85) 0.430 41.7 (5) 52.9 (45) 247
* p values for comparison of carriers and non-carriers
a Attacks associated to menstruation
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usually an adequate number for phenotype–genotype cor-
relation studies and sufﬁcient for most purposes. Thou-
sands of probands are needed to ﬁnd a genetic association
like the rs1835740 variant. However, if thousands of
patients are needed to show signiﬁcance of a difference of a
certain clinical feature between two groups, this difference
will not be of clinical importance. For analysis in relatively
small groups, e.g., males, our material is insufﬁcient. Most
importantly, the group of homozygotes was far too small
for a meaningful statistical analysis. It seems that if any
phenotypical correlate of the variant exists, it must be
found in this group. However, a very large material would
be necessary to get enough homozygous patients.
Migraine and glutamate
Marker rs1835740 is located between the two potentially
interesting genes, MTDH and PCGP, which are both
involved in glutamate homeostasis. The rs1835740
genotype was found by Antilla et al. to be signiﬁcantly
correlated to MTDH expression in lymphoblastoid cell
lines [10]. In astrocytes, MTDH has been shown to
downregulate GLT-1, the gene encoding the major glu-
tamate transporter. The new genetic variant may thus
contribute to the understanding of the role of glutamate in
migraine. Glutamate is involved in central sensitization
which is considered to be a crucial part of migraine
pathophysiology [21], and glutamate accumulation
increases the susceptibility to cortical spreading depres-
sion [22, 23].
Glutamate is the major excitatory neurotransmitter in
the CNS and therefore plays a crucial role in the mediation
of excitatory synaptic transmission [24]. The anatomic
structures involved in the migraine pain pathway, including
the trigeminal ganglion (TG), the trigemino-cervical com-
plex (TCC) and thalamus, contain glutamate-positive
neurons [25, 26]. Glutamate exhibits its actions through
activation of ionotropic and metabotropic receptors
(GluRs), and the pharmacological distinction of these is
well documented [27]. Glutamate is released from the TCC
in response to stimulation of dural structures. In TG neu-
rons, glutamate is released along with calcitonin gene-
related peptide (CGRP), and the majority of glutamatergic
neurons in TG carry 5-HT1B/D/F receptors, which could
possibly modulate glutamate release [28]. Glutamate also
Table 4 Effect of hormonal factors on migraine attack frequency, females only, in ‘migraine without aura’ patients divided in subgroups:
carriers and non-carriers of the rs1835740 variant, and homo- and heterozygotes of the rs1835740 variant
Attack frequency Unchanged Higher Lower Irrelevant Total number of answers
During pregnancy 252
Non-carriers 7.8 (12) 5.2 (8) 48.4 (74) 38.6 (59)
Hetero 11.5 (10) 2.3 (2) 40.2 (35) 46.0 (40)
Homo 0.0 (0) 0.0 (0) 41.7 (5) 58.3 (7)
Using birth-control pills 246
Non-carriers 38.0 (57) 20.0 (30) 5.3 (8) 36.7 (55)
Hetero 47.1 (40) 9.4 (8) 4.7 (4) 38.8 (33)
Homo 36.4 (4) 9.1 (1) 9.1 (1) 45.5 (5)
After meno pause 245
Non-carriers 10.8 (16) 7.4 (11) 6.8 (10) 75.0 (111)
Hetero 15.3 (13) 10.6 (9) 2.4 (2) 71.8 (61)
Homo 0.0 (0) 16.7 (2) 25.0 (3) 58.3 (7)
Table 5 Effect and use of medicine in ‘migraine without aura’ patients divided in subgroups: carriers and non-carriers of the rs1835740 variant,
and homo- and heterozygotes of the rs1835740 variant
Effect and use of medicine Carriers Non-carriers p* Homo Hetero Total number
of answers %( n)% ( n)% ( n)% ( n)
Effect of triptans 83.2 (94) 85.8 (145) 0.601 84.6 (11) 83.0 (83) 282
Effect of prophylactic medication 33.0 (37) 28.5 (49) 0.582 46.2 (6) 31.3 (31) 284
Under current prophylactic medication 35.4 (40) 32.0 (54) 0.548 23.1 (3) 37.0 (37) 282
Other current daily medication 36.0 (41) 35.1 (60) 0.879 23.1 (3) 37.6 (38) 285
Previous/current treatment of med. overuse headache 32.1 (36) 29.2 (50) 0.604 23.1 (3) 33.3 (33) 283
* p values for comparison of carriers and non-carriers
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information in the sensory thalamus [29, 30].
Migraineurs have elevated levels of glutamate and glu-
tamine in the cerebrospinal ﬂuid compared with controls,
and a positive correlation between glutamate levels and
mean headache scores has been reported [31–33]. Although
the variant only explains a small fraction of the overall
genetic variance, it increases the interest in glutamatergic
mechanisms in migraine.
Personalized medicine and future perspectives
There is still an unmet need to ﬁnd more effective, toler-
able and safe treatments for migraine, especially regarding
preventive agents. MO is clinically well deﬁned as a syn-
drome, but it has not been possible to divide MO into
subtypes based on clinical features. The tolerability, safety
and efﬁcacy of each type of preventive medicine are
individual for every patient and not predictable. Thus, ‘trial
and error’ is still the only possible treatment strategy. If a
certain genotype was associated with certain clinical fea-
tures, it would perhaps be possible to select patients for
treatment based on clinical criteria. Unfortunately, the
present study did not reveal a signiﬁcant difference in
clinical features according to the presence or absence of the
rs1835740 variant. Another approach would be to compare
the effect of drugs in patients with and without the variant.
Especially, the effects of glutamate-modulating agents
would be interesting to investigate. If this strategy gives
results and as the technology of genotyping gets more
economic and accessible, a future perspective could be to
select patients for treatment based on genotyping [34].
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